Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(2.08) per share. This is a 48 percent increase over losses of $(4.00) per share from the same period last year.
WNS (Holdings) Says It Expects FY25 Revenue Of $1.293B-$1.357B Vs. $1.36B Estimate; Projects FY25 Adjusted EPS Of $4.34-$4.59 Vs $4.54 Estimate
Revenue less repair payments* is expected to be between $1,293 million and $1,357 million, up from $1,284.3 million in fiscal 2024. Guidance assumes an average GBP to USD
